Liquid Biopsy Market Size, Share, Trends & Forecast
The Liquid Biopsy Market is entering a strong growth phase as demand increases for non-invasive diagnostic technologies and precision medicine. According to WiseGuyReports, the market was valued at USD 9.9 billion in 2025 and is projected to reach USD 29.7 billion by 2035, expanding at a CAGR of 11.6%.
The rising prevalence of cancer is a major factor supporting market expansion. Healthcare providers and diagnostic organizations are increasingly interested in technologies that can provide molecular information through less invasive approaches. This is encouraging investment in liquid biopsy platforms for cancer detection, monitoring, and related diagnostic applications.
Technological advancement is another important growth factor. Next-generation sequencing and digital PCR are improving the capabilities of liquid biopsy testing, while circulating tumor DNA is identified by the report as a particularly high-growth area. These technologies are broadening opportunities for diagnostics companies and research organizations.
The market is also benefiting from increasing interest in personalized medicine. Liquid biopsy technologies can support the analysis of biomarkers and molecular information, creating opportunities for more targeted diagnostic strategies and treatment monitoring. Continued research into additional biomarkers and cancer types could further expand the addressable market.
Looking ahead, greater clinical adoption, technology development, research investment, and expansion into emerging markets are expected to sustain the industry's momentum. Companies that combine sensitive testing technologies with scalable laboratory workflows and strong data-analysis capabilities may be well positioned for future growth.